# Avistone Biotechnology

Source: https://onco.cc/companies/avistone-biotechnology/  
OnCo record `avistone-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.

## Summary

Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Avistone Biotechnology Co., Ltd.
- Tags: ctgov-sponsor
- HQ: Beijing
- Type: biotech
- Website: https://www.avistonebio.com

## Sources

- Official website: https://www.avistonebio.com
- ClinicalTrials.gov: trials led by Avistone Biotechnology: https://clinicaltrials.gov/search?lead=Avistone%20Biotechnology%20Co.%2C%20Ltd.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- trials: [A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)](https://onco.cc/trials/nct06015503/), [A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07285148/), [A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07538804/), [Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations](https://onco.cc/trials/nct07336732/), [Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.](https://onco.cc/trials/nct06281964/), [Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive](https://onco.cc/trials/nct07063329/), [Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.](https://onco.cc/trials/nct06574347/), [Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI](https://onco.cc/trials/nct06343064/), [Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur](https://onco.cc/trials/nct06970782/)
- companies: [Apollomics](https://onco.cc/companies/apollomics/)

---
JSON: https://onco.cc/api/v1/entities/avistone-biotechnology.json